Clinical trials
Kidney Diseases trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Recruiting | 8 |
| Active, not recruiting | 6 |
| Terminated | 4 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Amgen | 2 |
| AstraZeneca | 2 |
| Bayer | 2 |
| Eli Lilly and Company | 2 |
| Genzyme, a Sanofi Company | 2 |
| GlaxoSmithKline | 2 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
| Takeda | 2 |
| The George Institute | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kidney Diseases | 40 |
| Renal Insufficiency, Chronic | 13 |
| Glomerulonephritis | 10 |
| Glomerulonephritis, IGA | 9 |
| Urologic Diseases | 9 |
| Diabetic Nephropathies | 6 |
| Kidney Failure, Chronic | 5 |
| Renal Insufficiency | 5 |
| Diabetes Mellitus, Type 2 | 4 |
| Nephritis | 4 |
Trials
Showing 26 to 40 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.